Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Reuters

02/05

Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609306504"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609306504\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609306504?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609306504","market":"nz","top_or_hot":-1,"title":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCo-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLDfdBs:1","article_id":"2609306504","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609306504","pubTimestamp":1770300105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. , has received a license from the Central Drugs Standard Control Organization  to manufacture the CoSara PCR Pro real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis  and human papillomavirus , require separate regulatory clearance and are not yet available for sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4082":"医疗保健设备","CODX":"Co-Diagnostics, Inc."},"translate_title":"Co-Diagnostics合资企业CoSara获得CDSCO许可在印度生产PCR Pro仪器","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CODX":0.9},"content_text":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    \n\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}